STOCKHOLM, Jan. 13, 2021 /PRNewswire/ — On Tuesday January 12th, in Character Communications, robust preclinical success for a new COVID-19 vaccine, formulated by the team of Prof. Salanti from University of Copenhagen, ExpreS2ion Biotech, its joint undertaking partner AdaptVac and the Protect against-nCoV consortium, was published. Based mostly on these results, a clinical demo software (CTA) for a medical Phase I/II examine for the COVID-19 vaccine has been submitted.
About the preclinical effects
Readouts from the information clearly show that ABNCoV2 has the potential to be the very best-in-class COVID-19 vaccine with a more than 100-fold bigger amount of neutralizing antibodies in comparison with printed preclinical animal facts from presently authorized COVID-19 vaccines, this sort of as Pfizer-BioNTech’s, Moderna’s, and AstraZeneca-Oxford’s vaccines. The full paper is available on the internet and can be go through here.
About the CTA
The Scientific demo application (CTA) for the ABNCoV2 capsid virus-like particle (cVLP) dependent COVID-19 vaccine was submitted to the Central Committee on Investigate Involving Human Topics (CCMO) in the Netherlands past 7 days. It is expected to be accredited underneath a COVID-19 rapid-track assessment progress. This can be viewed as one more sizeable milestone pursuing the November 2020 announcement of the productive GMP manufacturing of the vaccine. ExpreS2ion expects to current preliminary scientific Stage I/IIa outcomes just before finish of Q1 2021.
Since March 2020, Attana has been aiding the crew of Prof. Ali Salanti at the University of Copenhagen in the improvement of this COVID-19 vaccine with two of Attana’s QCM Biosensors blended with research intelligence. As can be observed in the paper posted, Attana’s technologies has foremost been made use of to examine kinetic interactions involving RBD antigens and CLP-RBD to hACE2. On top of that, Attana and ExpreS2ion lately established a strategic partnership together with a source settlement of proteins. In addition, Attana engineering has been used to high-quality command the vaccine for the IND submission.
Attana CEO Teodor Aastrup remarks:
“I’m thrilled for our partners sake and for the long run of vaccine improvement and want to congratulate all parties associated for acquiring these exciting outcomes. I’m now hunting forward to check out this collaboration further and to with any luck , get the job done additional carefully with both equally Prof. Salanti and the crew at ExpreS2ion in the in the vicinity of time long term.”
For additional facts, remember to call:
+46 () 8 674 57 00
The Board of administrators for Attana take into account that the facts in this push launch is not probable to have a important result on the share cost but is of standard fascination for the shareholders and for this reason should really be communicated.
Attana was founded in 2002 with the vision of in-vitro characterization of molecular interactions mimicking in-vivo conditions. Because then, Attana has developed proprietary label no cost biosensors for biochemical, crude, sera, and cell-primarily based assays and the Attana Virus Analytics (AVA) system, a proprietary in-vitro diagnostics (IVD) resource. Attana merchandise and investigate companies are utilized by Huge Pharma, biotech companies and educational institutions inside of the everyday living sciences. To master more about our most up-to-date providers and products and solutions, you should visit www.attana.se or get hold of [email protected]
This details was brought to you by Cision http://news.cision.com
The adhering to data files are readily available for download: